Compare Stocks

→ Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CALA Calithera Biosciences	$0.02 -33.3%	$0.02	$0.01 ▼ $0.50	$97K	-0.17	877 shs	191 shs
KIN Kindred Biosciences	$9.25	$9.22	$3.46 ▼ $9.28	$420.52M	1.3	840,890 shs	178,496 shs
LXRX Lexicon Pharmaceuticals	$1.54 -3.8%	$2.28	$0.92 ▼ $3.79	$379.21M	1.27	4.38 million shs	1.69 million shs
OPTN OptiNose	$0.91 -2.2%	$1.48	$0.86 ▼ $2.10	$101.95M	-0.24	832,803 shs	23.36 million shs
REPH Recro Pharma		$1.73	$1.38 ▼ $3.79	$117.93M	1.08	126,298 shs	141,800 shs

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CALA Calithera Biosciences	0.00%	-27.50%	+45.00%	-3.33%	-27.50%
KIN Kindred Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%
LXRX Lexicon Pharmaceuticals	-0.62%	-1.23%	-24.53%	-10.11%	-32.20%
OPTN OptiNose	-4.38%	-9.28%	-38.31%	-36.62%	-47.72%
REPH Recro Pharma	0.00%	0.00%	0.00%	0.00%	0.00%

Better than Bitcoin? The Biotech Stock with 46,751% Potential (Ad)

4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.

Get the name of the stock here >>>

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CALA Calithera Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KIN Kindred Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	1.5941 of 5 stars	3.0	3.0	0.0	0.0	1.7	1.7	0.6
OPTN OptiNose	3.6308 of 5 stars	3.5	2.0	0.0	4.2	0.0	2.5	0.6
REPH Recro Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CALA Calithera Biosciences	N/A	N/A	N/A	N/A
KIN Kindred Biosciences	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	2.00	Hold	$5.00	224.68% Upside
OPTN OptiNose	3.00	Buy	$4.00	341.99% Upside
REPH Recro Pharma	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest OPTN, CALA, REPH, LXRX, and KIN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/23/2024	LXRX Lexicon Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold
4/11/2024	LXRX Lexicon Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold
3/18/2024	OPTN OptiNose	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
3/18/2024	OPTN OptiNose	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$3.00 ➝ $4.00
3/11/2024	OPTN OptiNose	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$5.00

(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CALA Calithera Biosciences	$9.75M	0.01	N/A	N/A	($0.40) per share	-0.05
KIN Kindred Biosciences	$42.16M	9.97	N/A	N/A	$1.75 per share	5.29
LXRX Lexicon Pharmaceuticals	$1.20M	316.01	N/A	N/A	$0.38 per share	4.05
OPTN OptiNose	$70.99M	1.44	N/A	N/A	($0.77) per share	-1.18
REPH Recro Pharma	$75.36M	0.00	N/A	N/A	$0.90 per share	0.00

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CALA Calithera Biosciences	-$39.65M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
KIN Kindred Biosciences	-$21.80M	-$0.55	N/A	N/A	N/A	-529.26%	-54.19%	-39.76%	N/A
LXRX Lexicon Pharmaceuticals	-$177.12M	-$0.80	N/A	N/A	N/A	-14,573.20%	-138.54%	-71.29%	5/7/2024 (Estimated)
OPTN OptiNose	-$35.48M	-$0.32	N/A	N/A	N/A	-50.06%	N/A	-33.05%	5/9/2024 (Estimated)
REPH Recro Pharma	-$11.37M	-$0.31	N/A	N/A	N/A	-15.15%	-56.66%	-11.14%	N/A

Latest OPTN, CALA, REPH, LXRX, and KIN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/11/2024	Q4 2023	LXRX Lexicon Pharmaceuticals	-$0.23	-$0.20	+$0.03	-$0.20	$0.68 million	$0.70 million
3/7/2024	12/31/2023	OPTN OptiNose	-$0.10	-$0.09	+$0.01	-$0.09	$19.90 million	$19.87 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CALA Calithera Biosciences	N/A	N/A	N/A	N/A	N/A
KIN Kindred Biosciences	N/A	N/A	N/A	N/A	N/A
LXRX Lexicon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OPTN OptiNose	N/A	N/A	N/A	N/A	N/A
REPH Recro Pharma	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CALA Calithera Biosciences	N/A	N/A	N/A
KIN Kindred Biosciences	0.19	7.02	7.02
LXRX Lexicon Pharmaceuticals	1.07	5.60	5.58
OPTN OptiNose	N/A	0.60	0.55
REPH Recro Pharma	2.27	3.24	2.74

Ownership

Institutional Ownership

Company	Institutional Ownership
CALA Calithera Biosciences	N/A
KIN Kindred Biosciences	66.89%
LXRX Lexicon Pharmaceuticals	74.70%
OPTN OptiNose	85.60%
REPH Recro Pharma	62.34%

Insider Ownership

Company	Insider Ownership
CALA Calithera Biosciences	6.60%
KIN Kindred Biosciences	13.69%
LXRX Lexicon Pharmaceuticals	6.80%
OPTN OptiNose	2.20%
REPH Recro Pharma	14.20%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CALA Calithera Biosciences	8	4.87 million	4.55 million	Not Optionable
KIN Kindred Biosciences	63	45.46 million	N/A	Optionable
LXRX Lexicon Pharmaceuticals	285	246.24 million	229.49 million	Optionable
OPTN OptiNose	132	112.65 million	110.17 million	Not Optionable
REPH Recro Pharma	185	56.42 million	48.41 million	Optionable

OPTN, CALA, REPH, LXRX, and KIN Headlines

Source	Headline
	Dorf Ketal's Indian unit acquires veterinary pharma brand vccircle.com - April 10 at 10:57 PM
	Fuji Pharma Co. Ltd. wsj.com - January 30 at 3:34 PM
	Aurobindo Pharma Q2 results: Net profit jumps 85% to Rs 757 crore moneycontrol.com - November 22 at 10:47 PM
	Retaining the human element of AI within pharma and healthcare pharmaphorum.com - November 21 at 10:06 AM
	Here's what Wall Street expects from Recro Pharma's earnings report markets.businessinsider.com - November 7 at 12:00 PM
	US supreme court halts Purdue Pharma deal that shields Sacklers from lawsuits theguardian.com - August 16 at 1:59 AM
	Mankind Pharma share price livemint.com - August 9 at 12:30 PM
	What Wall Street expects from Recro Pharma's earnings markets.businessinsider.com - August 9 at 7:25 AM
	Mankind Pharma Ltd (MNKI) investing.com - August 3 at 9:00 AM
	Eversana and Amazon plan generative AI push in pharma pharmaphorum.com - July 30 at 11:21 PM
	Aurobindo Pharma Ltd. ndtv.com - July 25 at 12:39 AM
	Baudax Bio acquires Maryland biotechnology firm TeraImmune; stock jumps bizjournals.com - June 30 at 12:44 PM
	Pharma reform: Patients can’t afford to wait. Act now. politico.eu - June 13 at 3:41 PM
	Sun Pharma reports "information security incident"; isolates impacted IT assets health.economictimes.indiatimes.com - March 9 at 7:26 AM
	Watch: Woody Harrelson Torches Big Pharma During Hilarious Opening Monologue on SNL ijr.com - March 2 at 12:30 AM
	Aurobindo Pharma shares gain even as Q3 profit sinks; board declares 300% dividend moneycontrol.com - February 17 at 8:43 PM
	Paytm, Adani Enterprises, HUL, Sun Pharma, Lupin, Cummins, GAIL, Macrotech Developers stocks in focus financialexpress.com - December 20 at 8:48 AM
	Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Recro Pharma, Inc. Common Stock – SCTL benzinga.com - June 24 at 9:08 AM
	Societal CDMO Inc reuters.com - April 20 at 9:24 AM
	Recro Pharma, Inc.: Recro Announces Name Change to Societal CDMO to Reflect Corporate Expansion and Transformation finanznachrichten.de - March 22 at 10:51 PM
	Recro Pharma Rebrands to Societal CDMO Inc. contractpharma.com - March 22 at 5:51 PM
	Is Recro Pharma (REPH) a Worthy Investment? finance.yahoo.com - March 22 at 8:32 AM
	Recap: Recro Pharma Q4 Earnings benzinga.com - March 1 at 11:55 PM
	Recro Pharma Progresses Addition of Fill/Finish, Lyophilization Capabilities contractpharma.com - February 23 at 9:51 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Calithera Biosciences

NASDAQ:CALA

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Kindred Biosciences

NASDAQ:KIN

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA.

Lexicon Pharmaceuticals

NASDAQ:LXRX

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

OptiNose

NASDAQ:OPTN

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.

Recro Pharma

NASDAQ:REPH

Recro Pharma, Inc. is a pharmaceutical company, which engages in the contract development and manufacturing organization (CDMO). The firm offers integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Exton, PA.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial